Lilly, Incyte’s baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO

? Rheumatoid arthritis drug Olumiant?? approved for a narrower-than-expected patient population earlier this year to the dismay of its manufacturer Eli?Lilly $LLY and Incyte $INCY which had blockbuster dreams for the drug?? may be worth its weight in gold if approved for lupus, a disease in which the immune system attacks its host, and has seen a solitary approved treatment in the last 50 years. The companies announced on Thursday that the drug, known chemically as?baricitinib, had been granted